Table:
Nsx Set: Category (No. of Cases) | Study Set Number | Abbreviated Classification/Diagnosis and Grade (if applicable) | H&E, FFPE | Special Stains | IHC | Total Slides | SPG Dx QCS (n = 3) | SPG SS/ IHC QCS (n = 3) | STG Dx QCS (n = 2) | STG SS/ IHC QCS (n = 2) | Diagnostic Image Quality, Yes/No |
---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
CNS/PNS neoplastic (10) | Nsx-01 | Central neurocytoma, WHO grade II | 1 | 0 | 4 (SYN, NeuN, GFAP, NF) | 5 | 0 | 0 | 0 | 0 | Yes |
Nsx-02 | Ependymoma, WHO grade II | 1 | 0 | 3 (GFAP, EMA, NF) | 4 | 0 | 0 | 0 | 0 | Yes | |
Nsx-03 | Glioblastoma, WHO grade IV | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
Nsx-04 | Oligodendroglioma, IDH-mutant and 1 p/19q codeleted, WHO grade II | 1 | 0 | 5 (mlDHl, ATRX, P53, GFAP, NF) | 6 | 0 | 0 | 0 | 0 | Yes | |
Nsx-05 | Myxopapillary ependymoma, WHO grade I | 1 | 1 (Al Bl) | 1 (GFAP) | 3 | 0 | 0 | 0 | 0 | Yes | |
Nsx-07 | Medulloblastoma, WHO grade IV | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
Nsx-09 | Hemangioblastoma, WHO grade I | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
Nsx-10 | Schwannoma, WHO grade I | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
Nsx-13 | Adamantinomatous craniopharyngioma, WHO grade I | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
Nsx-15 | Secretory meningioma, WHO grade I | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
CNS/PNS nonneoplastic (3) | Nsx-06 | Arteriovenous malformation | 1 | 1 (VVG) | 0 | 2 | 0 | 0 | 0 | 0 | Yes |
Nsx-08 | Neurocysticercosis | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
Nsx-11 | Cavernous malformation (cavernoma) | 1 | 1 (GT) | 0 | 2 | 0 | 0 | 0 | 0 | Yes | |
Brain autopsy neoplastic (1) | Nsx-14 | Intravascular B-cell lymphoma | 1 | 0 | 1 (CD20) | 2 | 0 | 0 | 0 | 0 | Yes |
Brain autopsy nonneoplastic (1) | Nsx-12 | Coccidioidal meningitis | 1 | 1 (GMS) | 0 | 2 | 0 | 0 | 0 | 0 | Yes |
Ophthalmic neoplastic (2) | Oph-1 | Uveal melanoma | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes |
Oph-3 | Invasive squamous cell carcinoma | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
Ophthalmic nonneoplastic (3) | Oph-2 | Hidrocy stoma | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes |
Oph-4 | Epidermal inclusion cyst | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Yes | |
Oph-5 | Lipogranuloma (chalazion) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | Yes | ||
Total | 20 | 20 | 4 | 14 | 38 | ||||||
Metabolic/mitochondrial myopathy (4) | NM-01 | GSD/acid maltase deficiency (glycogenosis type II) | 0/1 | 4 (mGT, PAS, ORO, AcP)/0 | 0/0 | 5 | 0 | 0 | 0 | 0 | Yes |
NM-02 | GSD/McArdle disease (glycogenosis type V) | 0/1 | 4 (MP, COX/SDH, ORO, PAS)/0 | 0/0 | 5 | 0 | 0 | 0 | 0 | Yes | |
NM-04 | Mitochondrial myopathy | 0/1 | 5 (mGT, MP, COX/ SDH, AMPD, PFK)/1 (MB) | 0/0 | 7 | 0 | 0 | 0 | 0 | Yes | |
NM-06 | Lipid storage disease | 0/1 | 2 (ORO, PAS)/1 (MB) | 0/0 | 4 | 0 | 0 | 0 | 0 | Yes | |
Dystrophic (1) | NM-07 | Necrotizing myopathy/dysferlinopathy | 0/1 | 0/0 | 4 (dysferlin, dystrophins (rod, C-term, N-term))/0 | 5 | 0 | 0 | 0 | 0 | Yes |
Immune/inflammatory (5) | NM-03 | Inflammatory myopathy/immune myopathy with prominent perimysial pathology | 0/1 | 2 (AcP, AlkP)/0 | 3 (HLA-I, CD3, CD20)/0 | 6 | 0 | 0 | 0 | 0 | Yes |
NM-05 | Inflammatory myopathy/sporadic inclusion body myositis | 0/1 | 0/1 (MB) | 4 (HLA-I, CD3, CD20, TDP43)/0 | 6 | 0 | 0 | 0 | 0 | Yes | |
NM-08 | Immune mediated/macrophagic myofasciitis | 0/1 | 2 (PAS, AcP)/1 (MB) | 0/0 | 4 | 0 | 0 | 0 | 0 | Yes | |
NM-09 | Immune-mediated neuropathy with axonopathy | 1/0 | 0/2 (MB, teased nerve fiber preparation) | 0/1 (CD 3) | 4 | 0 | 0 | 0 | 0 | Yes | |
NM-10 | Immune-mediated/vasculitis with axonopathy and neurogenic atrophya | 3/1 | 0/1 (MB) | 1 (CD3)/3 (CD3, CD68, NF) | 9 | 0 | 0 | 0 | 0 | Yes | |
Total | 10 | 4/9 | 19/7 | 12/4 | 55 |
Abbreviations: AcP, acid phosphatase; Al Bl, Alcian blue; AlK P, alkaline phosphatase; AMPD, myoadenylate deaminase; ATRX, a-thalassemia/mental retardation, X-linked; CNS, central nervous system; COX/SDH, cytochrome c oxidase/succinate dehydrogenase; DX, diagnosis; EMA, epithelial membrane antigen; FFPE, formalin fixed, paraffin embedded; Fzn, frozen; GFAP, glial fibrillary acidic protein; GMS, Grocott methenamine silver stain; GSD, glycogen storage disease; GT, Gomori trichrome; H&E, hematoxylin-eosin; HLA-I, human leukocyte antigen class I; IHC, immunohistochemical stains; MB, methylene blue; mGT, modified Gomori trichrome; mIDH, mutant isocitrate dehydrogenase; MP, myophosphorylase; NeuN, neuronal nuclear protein; NF, neurofilament; NM, neuromuscular; Nsx, neurosurgical; ORO, Oil Red O; PAS, periodic acid-Schiff; PFK, phosphofructokinase; PNS, peripheral nervous system; QCS, quality concern score; SPG, study pathologist group; SS, special stains; STG, study trainee group; SYN, synaptophysin; TDP43, TAR DNA-binding protein 43; VVG, Verhoeff-Van Gieson stain; WHO, World Health Organization.
Includes slides additionally provided per request of 1 SPG member (2 additional H&E stains and CD3 and CD68 IHC).